What is CrossRoads Extremity Systems?
CrossRoads Extremity Systems operates at the vanguard of minimally invasive foot surgery, specifically through its miniBunion 3D platform. The company addresses a significant clinical need by offering surgical interventions that utilize smaller incisions, thereby reducing patient trauma and accelerating recovery timelines. Unlike traditional, more invasive bunion correction techniques, the CrossRoads approach emphasizes immediate postoperative mobility, a key differentiator that has driven adoption among both surgeons and patients. With a business model designed for insurance compatibility, the company is effectively scaling its footprint to provide accessible, advanced orthopedic solutions to a wide demographic suffering from chronic bunion-related pathologies.
How much funding has CrossRoads Extremity Systems raised?
CrossRoads Extremity Systems has raised a total of $4.1M across 3 funding rounds:
Private Equity
$3M
Debt
$350K
Debt
$810K
Private Equity (2018): $3M, investors not publicly disclosed
Debt (2020): $350K led by PPP
Debt (2021): $810K supported by PPP
Key Investors in CrossRoads Extremity Systems
PPP
Public-Private Partnership
Undisclosed Private Equity
An investment firm specializing in late-stage capital deployment to drive market expansion and organizational scaling for healthcare innovators.
Undisclosed Institutional Backer
A strategic partner providing long-term capital to support the development and commercialization of proprietary orthopedic surgical systems.
What's next for CrossRoads Extremity Systems?
With the recent influx of capital, CrossRoads Extremity Systems is well-positioned to accelerate its market penetration and refine its surgical ecosystem. The strategic focus will likely shift toward expanding the availability of the miniBunion 3D procedure, potentially through increased investment in surgeon training programs and regional distribution networks. As the company matures, the integration of further technological advancements in foot surgery will be critical to maintaining its competitive edge. The current enterprise-level funding environment suggests that the firm is preparing for a phase of sustained growth, aiming to standardize its minimally invasive protocols as the new benchmark for bunion correction in the domestic healthcare market.
See full CrossRoads Extremity Systems company page
